This data corroborates our in vitro analysis, since as we have shown, higher amount of NRF2 and GSH mediate tumor resistance to cisplatin treatment, ultimately leading to a worse prognosis for lung cancer patients. This evidence concerns the gene NFE2L2 and lung carcinoma.